| Intermittent Fasting Accompanying Chemotherapy in Gynecological Cancers (NCT03162289) | Charite University, Berlin, Germany | 2017-05-10 |
| Circulating Tumour DNA as a Marker of Residual Disease & Response to Adjuvant Chemotherapy in Stage I-IV Ovarian Cancer (NCT03691012) | Walter and Eliza Hall Institute of Medical Research | 2017-05-09 |
| Effectiveness of Care in Certified Cancer Centres in Germany (NCT04334239) | Technische Universität Dresden | 2017-05-01 |
| Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers (NCT02830724) | National Cancer Institute (NCI) | 2017-04-06 |
| CAR T Cells in Mesothelin Expressing Cancers (NCT03054298) | University of Pennsylvania | 2017-04-06 |
| A Phase I Clinical Trial of Bevacizumab Injection (NCT05476341) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2017-04-06 |
| A Trial of Fast Access to Transvaginal Ultrasound Through General Practice for Earlier Diagnosis of Ovarian Cancer (NCT03069872) | University of Aarhus | 2017-04-05 |
| Development of a Decision Aid to Facilitate Ovarian Cancer Patient's Choices Regarding Biomarker CA125 (NCT03004391) | Vejle Hospital | 2017-04-01 |
| Evolution of the Therapeutic Care in Ovarian Cancer From 2011 (NCT03275298) | UNICANCER | 2017-04-01 |
| Homologous Recombination Inquiry Through Ovarian Malignancy Investigations (NCT03159572) | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | 2017-03-28 |
| An Observational Study of Combination of Pegylated Liposomal Doxorubicin and Trabectedin in Routine Practice in Patients With Recurrent Partial-platinum Sensitive Ovarian Cancer (NCT03446495) | Suriya Yessentayeva | 2017-03-28 |
| A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients (NCT03075462) | Jiangsu HengRui Medicine Co., Ltd. | 2017-03-09 |
| Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer (NCT03117933) | University of Oxford | 2017-03-09 |
| A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT03038100) | Hoffmann-La Roche | 2017-03-08 |
| Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (NCT03335241) | Sun Yat-sen University | 2017-03-01 |
| Defining Inflammation Related to Peritoneal Carcinomatosis in Women With Ovarian or Colon Cancer. (NCT04122937) | University of Pisa | 2017-03-01 |
| ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients (NCT02855944) | pharmaand GmbH | 2017-03-01 |
| A Study Evaluating MM-310 in Patients With Solid Tumors (NCT03076372) | Merrimack Pharmaceuticals | 2017-02-22 |
| A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer (NCT03042702) | Innovation Pharmaceuticals, Inc. | 2017-02-09 |
| Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer (NCT02948426) | National Cancer Institute (NCI) | 2017-02-08 |
| The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors (NCT03507543) | Impact Therapeutics, Inc. | 2017-02-03 |
| Vitamin D, Leptin, Vitamin D Receptor Polymorphism, and Treatment-Related Morbidity in Ovarian Cancer (NCT03028519) | University of Oklahoma | 2017-01-31 |
| Cost Utility of Radical Surgery in Ovarian Cancer (NCT02854215) | Institut Claudius Regaud | 2017-01-18 |
| Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE) (NCT03017573) | Institut Curie | 2017-01-06 |
| Long Term Survivors in Ovarian Cancer (NCT03128294) | University Medical Center Groningen | 2017-01-01 |
| Clinical and Pathological Characteristics of Women With Ovarian Cancers in Syria (NCT06253559) | Latakia University | 2017-01-01 |
| Carboplatin-cyclophosphamide Combined With Atezolizumab (NCT02914470) | The Netherlands Cancer Institute | 2017-01-01 |
| FLABRA: Frontline Approach for BRCA Testing in OC Treatment naïve Population. A LATIN AMERICA Epidemiologic Study (NCT02984423) | AstraZeneca | 2016-12-27 |
| Characterizing the Cross-sectional Approach to Ovarian Cancer: Genetic Testing of BRCA (NCT03229122) | AstraZeneca | 2016-12-26 |
| Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors (NCT02988817) | Genmab | 2016-11-23 |
| Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery (NCT02884648) | M.D. Anderson Cancer Center | 2016-11-15 |
| A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib (NCT02873962) | Dana-Farber Cancer Institute | 2016-11-10 |
| Phase I Trial: 68Ga-NODAGA-E(c[RGDyK])2 Positron Emission Tomography for Imaging Angiogenesis in Primary and Metastatic Tumor Lesions in Humans (NCT02970786) | Rigshospitalet, Denmark | 2016-11-01 |
| Study of Oncoimmunome for the Treatment of Stage III/IV Ovarian Carcinoma (NCT02933073) | UConn Health | 2016-11-01 |
| A Study With Intraperitoneal Cisplatin and Doxorubicin in Recurrent Ovarian Cancer and Peritoneal Carcinomatosis (NCT02475772) | Clemens Tempfer | 2016-11-01 |
| Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors (NCT02897375) | Emory University | 2016-10-24 |
| Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer (NCT02973750) | H. Lee Moffitt Cancer Center and Research Institute | 2016-10-20 |
| A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer (NCT02836028) | Pfizer | 2016-10-01 |
| Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer (NCT02766582) | Medical College of Wisconsin | 2016-10-01 |
| Individual Survivorship Program for Ovarian Cancer Patients Based on PROM's and Shared Decision Making (NCT02916875) | Vejle Hospital | 2016-10-01 |
| Role of Geriatric Intervention in Treatment of Older Patients With Cancer (PREPARE) (NCT02704832) | Institut Bergonié | 2016-09-30 |
| Prognostic and Predictive Biomarkers in Ovarian Cancers (NCT03010124) | Gustave Roussy, Cancer Campus, Grand Paris | 2016-09-26 |
| Factors Associated With the Use of a High Volume Cancer Center by Black Women With Ovarian Cancer: A Qualitative Study (NCT02928549) | Memorial Sloan Kettering Cancer Center | 2016-09-22 |
| ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab (NCT02891824) | ARCAGY/ GINECO GROUP | 2016-09-22 |
| Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer (NCT02865811) | Dana-Farber Cancer Institute | 2016-09-15 |
| MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors (NCT02669914) | Washington University School of Medicine | 2016-09-12 |
| Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors (NCT02869217) | University Health Network, Toronto | 2016-09-01 |
| Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer (NCT02867956) | Sun Yat-sen University | 2016-08-10 |
| HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life (NCT03000192) | University Hospital Southampton NHS Foundation Trust | 2016-08-01 |
| A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer (NCT02489006) | University Health Network, Toronto | 2016-07-19 |
| Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer (NCT02672098) | Loma Linda University | 2016-07-14 |
| Evaluating an Alternative Clinical Genetics Cancer Care Delivery Model: A Pilot Study of Patient Outcomes (NCT02917798) | Memorial Sloan Kettering Cancer Center | 2016-07-12 |
| A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) (NCT02576665) | Tocagen Inc. | 2016-07-01 |
| Trial on Radical Upfront Surgery in Advanced Ovarian Cancer (NCT02828618) | AGO Study Group | 2016-07-01 |
| Primary Debulking Surgery Including Bowel Resection in Advanced Stage Ovarian Cancer Using Caiman® Technology (NCT03219242) | Catholic University of the Sacred Heart | 2016-06-30 |
| A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer (NCT02661815) | Dana-Farber Cancer Institute | 2016-06-15 |
| Data and Specimen Bank of Patients Diagnosed With, and at High-risk for, Gynecologic Cancers (NCT04170712) | University of Virginia | 2016-06-10 |
| Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers (NCT02725489) | Mary Crowley Medical Research Center | 2016-06-03 |
| A Pilot Study Investigating the Effect of Chemotherapy on the Tumoral Immunoprofile of Gynecologic Cancers (NCT02824328) | Duke University | 2016-06-01 |
| Molecular Imaging and Spectroscopy With Stable Isotopes in Oncology and Neurology (NCT03526809) | Cambridge University Hospitals NHS Foundation Trust | 2016-06-01 |
| Restrictive or Individualized Goal-Directed Fluid Replacement Strategy in Ovarian Cancer Cytoreductive Surgery (NCT03519165) | Tata Medical Center | 2016-06-01 |
| Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100) (NCT02718417) | Pfizer | 2016-05-19 |
| Mesenchymal Stem Cells (MSC) for Ovarian Cancer (NCT02530047) | M.D. Anderson Cancer Center | 2016-05-16 |
| A Study of LY2880070 in Participants With Advanced or Metastatic Cancer (NCT02632448) | Esperas Pharma Inc. | 2016-05-16 |
| TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer (NCT02764333) | Memorial Sloan Kettering Cancer Center | 2016-05-06 |
| Predictive Biomarkers for IGF1R Targeted Therapy in Ovarian Cancer (NCT02711865) | Hillel Yaffe Medical Center | 2016-05-01 |
| MR-HIFU for Recurrent Gynaecological Cancer (NCT02714621) | Institute of Cancer Research, United Kingdom | 2016-05-01 |
| Molecular Mechanisms Leading to Chemoresistance in Epithelial Ovarian Cancer (NCT02758652) | Tampere University Hospital | 2016-05-01 |
| Expression of Altered Glycosyltransferases, Mucins, and RTKs in Human Ovarian and Endometrial Cancers (NCT02638402) | National Taiwan University Hospital | 2016-05-01 |
| Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer (NCT02759588) | Genelux Corporation | 2016-05-01 |
| A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer (NCT02681237) | University Health Network, Toronto | 2016-04-29 |
| Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer (NCT02657889) | Tesaro, Inc. | 2016-04-15 |
| A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer (NCT02737787) | Memorial Sloan Kettering Cancer Center | 2016-04-01 |
| An Audit of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (NCT02754115) | Tata Memorial Centre | 2016-04-01 |
| Treatment for Malignant Ovarian Cancer: Laparoscopy vs Laparotomy (NCT02686463) | Shengjing Hospital | 2016-04-01 |
| Predictive Biomarkers for IGF1R Targeted Therapy in Ovarian Cancer: a Retrospective Study (NCT02719041) | Hillel Yaffe Medical Center | 2016-04-01 |
| LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies (NCT02649673) | SCRI Development Innovations, LLC | 2016-03-23 |
| Guangzhou Women's Health Cohort Study (GWHCS) (NCT05506800) | Guangzhou Women and Children's Medical Center | 2016-03-03 |
| A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer (NCT02631876) | ImmunoGen, Inc. | 2016-03-02 |
| Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program (NCT02585362) | Kantonsspital Winterthur KSW | 2016-03-01 |
| A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer (NCT02713984) | Zhi Yang | 2016-03-01 |
| Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer (NCT02567253) | University Hospital, Ghent | 2016-03-01 |
| Fermented Wheat Germ Extract in Women With Ovarian Cancer (NCT02411565) | H. Lee Moffitt Cancer Center and Research Institute | 2016-03-01 |
| Study of the Isotopic Distribution of Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Ovarian Origin (NCT02667925) | Centre Jean Perrin | 2016-03-01 |
| PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer (NCT02571725) | New Mexico Cancer Research Alliance | 2016-02-23 |
| A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer (NCT02608684) | Cedars-Sinai Medical Center | 2016-02-08 |
| Advanced Methods for Cancer Detection by Vaginal Screening (NCT02622776) | Anna Tinker | 2016-02-01 |
| Study of Prolanta™ in Recurrent or Persistent Epithelial Ovarian Cancer (NCT02534922) | Oncolix, Inc. | 2016-02-01 |
| Mobile Phone Technology to Increase Genetic Counseling (NCT02877862) | University of Minnesota | 2016-02-01 |
| Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary Presentation (NCT02664389) | University Hospital, Rouen | 2016-02-01 |
| Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations (NCT02607813) | Novartis Pharmaceuticals | 2016-01-18 |
| Physician-Patient Communication and Expectations Regarding Ovarian Cancer Prognosis (NCT02769546) | Abramson Cancer Center at Penn Medicine | 2016-01-01 |
| Expectations and Priorities of Elderly Patients for a First Medical Treatment for Cancer (NCT02821793) | Institut Bergonié | 2016-01-01 |
| Development and Validation of a Prediction Model for AKI Following Cisplatin-Based HIPEC in Patients With Ovarian Cancer (NCT06697613) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2016-01-01 |
| International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) (NCT03210298) | Sabine Rhode | 2016-01-01 |
| Ovarian Malignancy Incidence in Moderate Risk Women With Low CA 125 (NCT02247323) | Beni-Suef University | 2016-01-01 |
| A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200) (NCT02580058) | Pfizer | 2015-12-21 |
| MRI-Guided Stereotactic Body Radiation Therapy (SBRT) for Ovarian Cancer (NCT02582931) | Washington University School of Medicine | 2015-12-02 |
| Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer (NCT02431559) | Ludwig Institute for Cancer Research | 2015-12-02 |
| Laboratory Study of Cancer & Immune Cells in Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies (NCT03943316) | New Mexico Cancer Research Alliance | 2015-12-02 |